Skip to main content
. 2022 Nov 1;12(10):146. doi: 10.1038/s41408-022-00741-2

Fig. 2. Cumulative incidence of CRS in lymphoma patients treated with anti-CD19 CAR T cells.

Fig. 2

Time to grade ≥2 CRS (A) or grade ≥3 CRS (B) were estimated. Patients were stratified by whether they received prophylactic G-CSF (N = 140) or not (control, N = 57), and compared using the method of Gray. The cumulative incidence of grade ≥2 CRS was significantly greater in the prophylactic G-CSF group (P < 0.01). In a multivariate Cox proportional hazards model, administration of prophylactic G-CSF prior to CAR T retained significance for increased risk of grade ≥2 CRS (HR 2.15, 95% CI 1.11–4.18, P = 0.02) (see Table 4). 95% confidence intervals are represented by shading.